Abbott Laboratories ABT · NYSE
$102.67 +2.15% (+$2.16)
Summary
54 / 100 · Bulios Score
What speaks for it
- It has raised its dividend 12 years in a row.
- Out of every 100 USD of revenue, 12 USD is left as net profit.
- Analysts expect revenue to grow by 13% this fiscal year.
What to watch
- The share price is above the Bulios Fair Price.
- Revenue grew by only 0.5% a year over the last 3 years.
- It earns only 6.1 USD a year on every 100 USD of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 33.2 USD for 1 USD of yearly profit. Over the last five years it was 29.1 USD on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 5.1% a year over 5 years. Over the last 3 years it grew by 0.5% a year. For the next fiscal year analysts expect revenue to grow by 13%. Earnings per share fell by 1.6% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 43 USD
- Research and development 6.8 USD
- Sales and administration 33 USD
- Taxes and other 5.4 USD
- Net profit 12 USD
Net profit, industry median (Medical - Devices) 6.9 USD
Out of every 100 USD of revenue, 12 USD is left as net profit.
Profitability in detailIs it financially healthy?
MostlyRepaying all its debt would take 3.7 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, stretched- Yield
- 2.42%
- Paid out of profit
- 80%
- Raised in a row
- 12 years
You receive $2.52 per share a year. The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 33
- Hold 9
- Sell 0
Today's price within the analysts' price targets
The average target of $122.7 is 19% above today's price. 79% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Medical Devices 48%
- Diagnostic Products 20%
- Nutritional Products 19%
- Established Pharmaceutical Products 12%
By region
- UNITED STATES 40%
- Non-US 37%
- D [E] 6.4%
- C [N] 4.4%
- C [H] 4.4%
- Other 7.8%
Medical Devices brings in 48% of revenue.
Segments in detail